title: Ifosfamide and mesna for the treatment of advanced squamous cell head and neck cancer. A GETLAC study.
abstract: High-dose ifosfamide/mesna was administrated to 28 mostly pretreated patients with locally advanced and metastatic head and neck cancer who failed conventional surgery/radiation treatment. Primary sites include tongue (5), salivary gland (3), floor of mouth (5), oropharynx (2), hypopharynx (5) and larynx (8). The dose and schedule of ifosfamide (IF) was 3.5 g/m2 8 h, i.v. infusion, days 1-5, every 28 days, and mesna was given as 20% of IF dose intravenous bolus injection at 0, 2, 4, 6 and 8 h; mesna 40% of IF dose was given by oral route at 10 and 12 h, days 1-5, every 28 days. All patients were evaluable for both toxicity and response. 14 patients had received prior treatment with surgery plus radiation therapy and 14 patients radiation therapy. Following chemotherapy, 4 patients (14.2%) achieved complete remission and 8 patients (28.5%) achieved partial remission, with an overall response rate of 42.7%. Toxicity was reported for 186 cycles and ranged from mild to moderate: anemia 4, leukopenia 6, thrombopenia 1, nausea and vomiting 12, alopecia 28, microscopic hematuria 3, increased transaminase 1. No CNS symptoms and renal toxicity were registered. Median duration of survival is 11+ months (range 3+ to 18+ months). Nine patients died. We conclude that ifosfamide/mesna at this dose and schedule has a significant activity in recurrent head and neck cancer, and produces minimal toxicity.
authors.affiliation: Hospital Prof, Dr. Bernardo Houssay, Vicente Lopez, Buenos Aires, Argentina.
authors.forename: J C
authors.initials: JC
authors.lastname: Cervellino
authors.forename: C E
authors.initials: CE
authors.lastname: Araujo
authors.forename: C
authors.initials: C
authors.lastname: Pirisi
authors.forename: A
authors.initials: A
authors.lastname: Francia
authors.forename: R
authors.initials: R
authors.lastname: Cerruti
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage*; D008297:Male; D015080:Mesna / Q000008:administration & dosage*; D008875:Middle Aged
chemical_list: D015080:Mesna; D007069:Ifosfamide